Knobbe, Martens, Olson & Bear, LLP
Crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, preparing method and use thereof
A crystal form I of (S)-4-hydroxy-2-oxo-1-pyrrolidine acetamide, or named (S)-oxiracetam, is provided, which is characterized by a powder x-ray diffraction pattern that exhibits data of d-values versus the relative intensities as: 7.075(M), 5.355(S), 5.092(S), 4.590(M), 4.325(M), 4.259(S), 4.041(VS), 3.808(M), 3.542(M), 3.445(M), 3.393(M), 2.972(M), 2.914(S). A method for preparing a crystal form I of (S)-oxiracetam is also provided, which includes preparing the crude product and crystallizing A use of the crystal form I of (S)-oxiracetam in the manufacture of a medicament for preventing and treating memory dysfunction is also provided. Accordingly, the crystal form I of (S)-oxiracetam prepared by the method has high purity of more than 99.3% based on the percentages of the mass, with better efficacy than (S)-oxiracetam for preventing or treating memory dysfunction. Concerning the way of charging materials, adding inorganic base only a few times is simpler and more beneficial to industrial manufacturing and application.
CHONGQING RUNZE PHARMACEUTICAL CO., LTD.
C A
C07D A61P
inventional inventional
Yuying Lei Qi Lei Chao Zuyuan Hua Nan Bo Fei
Chen Ye Pang Jin You Rong Feng Xu Li Li